RenLite：用于开发全人双抗 

RenLite小鼠具有全人抗体重链可变区及固定轻链。用于开发全人双特异性抗体。

• 全人抗体RenLite小鼠：基于SUPCE超大片段染色体工程技术获得。

• 具与人类相似的多样化重链库。
• RenLite来源的共轻链抗体组装双抗时错配率低，具有理想的理化性质。

• RenLite小鼠的免疫应答和野生小鼠一样强健。
• RenLite来源抗体具有亚纳摩尔范围内的高结合亲和力。

海报下载

IO Summit Europe 2024: Fully human conditional agonist 4-1BB×CD40 bispecific antibody exhibits potent in vitro and in vivo efficacy

AACR2024: BCG020, a novel bispecific antibody targeting EGFR and CD70, is effective against EGFR and CD70 high expressed tumors

Advancing Bispecific Antibody Discovery using a Common Light Chain Immunoglobulin Humanized Mouse

相关新闻

百奥赛图宣布与杨森达成RenLite授权协议